Currently, the only large‐scale outcome trial underway is MARITIME‐HF (NCT07037459), which will randomize 5056 patients with obesity and HFpEF to receive once‐monthly subcutaneous maridebart cafraglutide (known as MariTide; a GLP‐1 RA with GIP antagonism) or placebo, with the primary endpoint of time to first CV death or HF event. Here, GIP is linked to obesity due to melanocortin 4 receptor deficiency.